{
  "response": {
    "text": "Based on the search results, here's the information you requested, focusing on studies comparing Tasquinimod monotherapy to placebo in prostate cancer:\n\n**Study 1:**\n\n*   **Reference:** A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy.\n*   The median rPFS was 31.7 weeks in the tasquinimod arm and 22.7 weeks in the placebo arm.\n*   The second author cannot be determined from the abstract.\n\n**Study 2:**\n\n*   **Reference:** Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer (Sternberg et al., 2016).\n*   This phase III trial compared tasquinimod to placebo in men with chemotherapy-naive mCRPC and bone metastases.\n*   The primary endpoint was radiographic PFS.\n*   **SA**Andrew Armstrong\n",
    "citations": [
      "https://www.ncbi.nlm.nih.gov/sites/pubmed?cmd=search&term=Bellmunt%20J%5Bau%5D&dispmax=50",
      "http://www.activebiotech.com/tasq",
      "https://nampt-receptor.com/index.php/tasquinimod/"
    ]
  }
}